Calendar
Filter Events
January 2021
Evolving Models to Support the Expanding Role of the Pharmacist
MEMBERS
February 2021
The 117th Congress and Biden Administration – Health Care Legislative and Regulatory Outlook
MEMBERS
February 2021
What Makes a Drug “Special?” – Defining Specialty Medications
MEMBERS
February 2021
A new treatment for ANCA Associated Vasculitis, a rare orphan disease
A Preapproval Information Exchange (PIE) Webinar sponsored by ChemoCentryx.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement.
Already a Member of FormularyDecisionsSM
To register for this webinar, log into FormularyDecisionsSM and click on the “Register” link found on the home page in the Webinars section.
Not Yet a Member of FormularyDecisionsSM
If you are a healthcare decision maker but not yet a member of FormularyDecisionsSM, you can become a member by using the “Not Registered?” link at the top of the FormularyDecisionsSM homepage. Once you are a member registered as a payer, you can click on the “Register” link found on the home page in the Webinars section. Please contact registration@formularydecisions.com for assistance registering with FormularyDecisionsSM.
MEMBERS
NON-MEMBERS
February 2021
The Evidence Behind COVID-19 Treatments and Vaccines
This educational activity is supported by an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
This live program is accredited for 1.0 contact hours for pharmacists.
MEMBERS
NON-MEMBERS
March 2021
Preparing for and Managing Rare Diseases - Proceedings from the AMCP Partnership Forum
MEMBERS
NON-MEMBERS
March 2021
March 2021
Partnership Forum — Racial Health Disparities: A Closer Look at Benefit Design
Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. These health disparities result in avoidable readmissions, reduced quality of care, higher costs, and lower member satisfaction rates. Health care providers, insurers, and managed care pharmacy stakeholders need to identify organizational and system-based solutions to address systemic racial health disparities, including training Pharmacy & Therapeutics (P&T) committees properly on racial health equity, gaining a better understanding of best practices that can decrease racial health disparities related to benefit design, and disseminating these best practices.
This event is invitation-only. If you're interested in participating, please email corpopportunities@amcp.org.
INVITE ONLY
March 2021
Achieving Health Equity for Underserved Populations With Multiple Sclerosis (MS)
A Science & Innovation Webinar sponsored, developed and presented by Biogen.
MEMBERS
NON-MEMBERS
April 2021
AMCP 2021
Call for Poster Abstracts - Closed Dec. 1, 2020
Call for Session Proposals - Closed Oct. 18, 2020
August 2021
Partnership Forum — Digital Therapeutics 2.0: The Evolving Role of Digital Therapeutics
The role of digital therapies in preventing, managing, and treating medical conditions has evolved greatly in the past few years. They may be used independently or taken in tandem with other therapies to optimize clinical outcomes for patients. As innovative therapies are introduced into the market, challenges with developing evidence-based coverage criteria and tracking utilization have been identified. Forum participants will outline key barriers and develop solutions to support the appropriate use and coverage of digital therapeutics in the health care system.
This event is invitation only. If you're interested in participating, please email corpopportunities@amcp.org.
INVITE ONLY
October 2021
AMCP Nexus 2021
November 2021
Partnership Forum — Addressing Evidence Gaps in the Expedited Approval Process: Payer Perspectives
Drug development is expensive, time consuming, and risky. To address these factors, clinical and regulatory experts in pharmaceutical companies must design drug development programs and clinical trials that meet FDA requirements. Especially with drugs approved via expedited pathways, the payers’ perspective typically takes a back seat to FDA approval criteria. Further, payer expectations for efficacy and safety, as well as population parameters, can differ from those established to meet FDA stipulations. However, meeting payers’ expectations is critical for patient access and commercial success. Payers increasingly demand demonstration of long-term value, especially for high investment medications or those with a high-risk safety profile. Despite the rigorous steps in the process of drug development, limitations exist due to the difference between FDA approval requirements and payer evidence needs. Forum participants will outline payer needs, barriers, and solutions for products approved through an expedited approval process regarding evidence for new drug products.
This event is invitation-only. If you're interested in participating, please email corpopportunities@amcp.org.
INVITE ONLY